Promotional materials for a handful of biologics have found their way into the FDA’s hot seat. | Promotional materials for a ...

Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) has received approvals for two new indications in classical Hodgkin Lymphoma ...

Bristol Myers Squibb (BMS) plans to buy out its partner in developing the blockbuster multiple myeloma drug Abecma ® (idecabtagene vicleucel), by agreeing to acquire 2seventy bio for approximately ...

While it is common to hear that drug developers are in the early stages of integrating artificial intelligence with their drug research, discovery, and development efforts, one Bristol Myers Squibb ...

Bristol-Myers Squibb has announced its new-look leadership after the Celgene takeover goes through, and it reveals a mixed bag of new hires, sideways moves, and departures. The headline news is that ...

Bristol Myers Squibb’s highly anticipated Cobenfy just finished its first trip around the sun as an approved drug, posting results in line with expectations that leave investors wondering when an ...

Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe ...